Scholar Rock Holding Corporation (SRRK) Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA Research and Clinical Care meeting, which is being held in conjunction with Cure SMA’s Annual SMA Conference (June 15-19, 2022).

Read the source article at Financial Research & Reports Finder
2022-06-10 00:02:00